PMID- 36769555
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230413
IS  - 2077-0383 (Print)
IS  - 2077-0383 (Electronic)
IS  - 2077-0383 (Linking)
VI  - 12
IP  - 3
DP  - 2023 Jan 23
TI  - The Peculiarity of Infection and Immunity Correlated with Guillain-Barre Syndrome 
      in the HIV-Infected Population.
LID - 10.3390/jcm12030907 [doi]
LID - 907
AB  - Guillain-Barre syndrome (GBS) can occur at all stages of human immunodeficiency 
      virus (HIV) infection. HIV, cytomegalovirus (CMV), and varicella zoster virus 
      (VZV) are the main infectious agents in HIV-positive GBS cases. These cases 
      include acute and chronic HIV infection, immune reconstitution inflammatory 
      syndrome (IRIS) shortly after anti-retroviral therapy (ART), those with ART 
      interruption, or those with cerebrospinal fluids (CSF) HIV escape. The mechanisms 
      are involved in both humoral and cellular immunities. Demyelinating and axonal 
      neuropathies are the main pathological mechanisms in GBS. Presentation and 
      prognosis are identical to those in patients without HIV infection. Typical or 
      atypical clinical manifestations, CSF analysis, electrophysiological and 
      pathological examination, and antiganglioside antibody detection can help 
      diagnose GBS and classify its various subtypes. Intravenous immunoglobulin and 
      plasma exchange have been used to treat GBS in HIV-positive patients with a 
      necessary ART, while ganciclovir or foscarnet sodium should be used to treat 
      ongoing CMV- or VZV-associated GBS. Steroids may be beneficial for patients with 
      IRIS-related GBS. We reviewed HIV-positive cases with GBS published since 2000 
      and summarized their features to highlight the necessity of HIV testing among 
      patients with GBS. Moreover, the establishment of a multidisciplinary team will 
      guarantee diagnostic and therapeutic advantages.
FAU - Wang, Yanli
AU  - Wang Y
AD  - Department of Infectious Diseases, The First Affiliated Hospital of China Medical 
      University, Shenyang 110001, China.
FAU - Yang, Jun
AU  - Yang J
AD  - Neurology Department, The First Affiliated Hospital of China Medical University, 
      Shenyang 110001, China.
FAU - Wen, Ying
AU  - Wen Y
AD  - Department of Infectious Diseases, The First Affiliated Hospital of China Medical 
      University, Shenyang 110001, China.
LA  - eng
PT  - Editorial
DEP - 20230123
PL  - Switzerland
TA  - J Clin Med
JT  - Journal of clinical medicine
JID - 101606588
PMC - PMC9917483
OTO - NOTNLM
OT  - GBS
OT  - HIV
OT  - immunity
OT  - infection
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2023/02/12 06:00
MHDA- 2023/02/12 06:01
PMCR- 2023/01/23
CRDT- 2023/02/11 01:27
PHST- 2022/11/22 00:00 [received]
PHST- 2023/01/05 00:00 [revised]
PHST- 2023/01/16 00:00 [accepted]
PHST- 2023/02/11 01:27 [entrez]
PHST- 2023/02/12 06:00 [pubmed]
PHST- 2023/02/12 06:01 [medline]
PHST- 2023/01/23 00:00 [pmc-release]
AID - jcm12030907 [pii]
AID - jcm-12-00907 [pii]
AID - 10.3390/jcm12030907 [doi]
PST - epublish
SO  - J Clin Med. 2023 Jan 23;12(3):907. doi: 10.3390/jcm12030907.